NGF and neoplasm: Using a mouse model of prostate cancer-induced bone pain, the anti-NGF was administered both early, starting on day 14 after tumor injection, when nerve sprouting had not yet occurred, and late, starting on day 35, when extensive nerve sprouting had already occurred.